Anthera Pharmaceuticals, which is developing anti-inflammatory therapies for acute coronary syndrome and lupus, plans to raise $64 million by offering 4.6 million shares at a price range of $13-$15. At the mid-point of the proposed range, Anthera Pharmaceuticals will command a market value of $242 million. Anthera, which was founded in 2004, has yet to generate product revenue and is currently set to launch a Phase 3 trial for its lead drug candidate. The Hayward, CA-based company plans to list on the NASDAQ under the symbol ANTH. Deutsche Bank is the lead underwriter on the deal, which is expected to price this Tuesday, Feb. 23.
